Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | Director | May 20, 2021 | May 24, 2021 |
| Moderna, Inc.MRNA · Entity 2025 | President | September 14, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date May 20, 2021 · Filed May 24, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2031-05-19 | Direct | 20,000 |
Reported balance
After 2021-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-20 · Grant · Acquired 20,000 · Balance 20,000 F1: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting.
Moderna, Inc.
Report date September 14, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,562,029 |
Ending reported balance
After 2026-09-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-14 · Exercise / conversion · Acquired 76,453 · Balance 1,566,152 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. Row 2 · 2026-09-14 · Sale · Disposed 40,294 · Balance 1,525,858 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 3 · 2026-09-15 · Exercise / conversion · Acquired 76,452 · Balance 1,602,310 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. Row 4 · 2026-09-15 · Sale · Disposed 40,281 · Balance 1,562,029 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2027-02-23 | Direct | 382,262 |
Reported balance
After 2026-09-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-14 · Exercise / conversion · Disposed 76,453 · Balance 382,262 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F5: This option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2027-02-23 | Direct | 305,810 |
Reported balance
After 2026-09-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-15 · Exercise / conversion · Disposed 76,452 · Balance 305,810 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F5: This option is fully vested and exercisable. |
| Common StockSEC Table I · non-derivative | IndirectBy Valhalla, LLC | 4,116 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 4,116 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 151,933 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 151,933 F4: These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4: These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F5: This option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2020 Filed Mar 16, 2020 20:21 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,874 | $23.55 | $44,132.70 |
DisclosureSEC source: 0001127602-20-010788 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,051,630 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.12 to $23.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 20:21 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 3,026 | $22.56 | $68,266.56 |
DisclosureSEC source: 0001127602-20-010788 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,053,504 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.07 to $23.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:39 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 38,565 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-009039 · form4.xml · derivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,565 Underlying: Common Stock · 38,565 shares Expires not disclosed F2 · derivative.exercise_date: 50% of this restricted stock unit will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. F2 · derivative.expiration_date: 50% of this restricted stock unit will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:39 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 214,826 | $0.00 Strike: $25.93 | $0.00 |
DisclosureSEC source: 0001127602-20-009039 · form4.xml · derivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,826 Underlying: Common Stock · 214,826 shares Expires 2030-02-28 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 21:22 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,000 | $18.67 | $186,700.00 |
DisclosureSEC source: 0001127602-20-007602 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,056,530 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.36 to $19.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:25 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $19.23 | $96,150.00 |
DisclosureSEC source: 0001127602-20-005649 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,066,530 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.90 to $19.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:25 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $19.44 | $97,200.00 |
DisclosureSEC source: 0001127602-20-005649 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,071,530 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.25 to $19.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 24, 2020 Filed Jan 27, 2020 21:08 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $21.22 | $106,100.00 |
DisclosureSEC source: 0001127602-20-002437 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,076,530 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.98 to $21.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 21:08 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 385 | $22.53 | $8,674.05 |
DisclosureSEC source: 0001127602-20-002437 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,081,530 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.50 to $22.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 21:08 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 4,615 | $21.95 | $101,299.25 |
DisclosureSEC source: 0001127602-20-002437 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,081,915 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.47 to $22.46. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 13, 2020 Filed Jan 14, 2020 23:08 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,000 | $19.14 | $191,400.00 |
DisclosureSEC source: 0001127602-20-001577 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,086,530 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.68 to $19.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 22, 2019 Filed May 24, 2019 20:04 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $14.28 | $0.00 |
DisclosureSEC source: 0001104659-19-031779 · a4.xml · derivative · entry 1 Hoge Stephen · CIK 0001760669 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2029-05-21 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 21:31 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 339,195 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-19-010856 · form4.xml · derivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,195 Underlying: Common Stock · 339,195 shares Expires 2029-03-08 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 21:31 UTC | Moderna, Inc. MRNA · Entity 2025 | ConversionSeries E Preferred Stock · Derivative | 458 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030879 · doc4.xml · derivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 458 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series E Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45859 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. F1 · price: The Series E Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45859 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series E Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45859 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series E Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45859 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 21:31 UTC | Moderna, Inc. MRNA · Entity 2025 | ConversionCommon Stock | 458 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030879 · doc4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,096,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series E Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45859 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.